These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11228338)

  • 21. Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time.
    Fenyvesi T; Jörg I; Weiss C; Harenberg J
    Thromb Res; 2003; 111(1-2):89-94. PubMed ID: 14644085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma.
    Koestenberger M; Cvirn G; Gallistl S; Kutschera J; Muntean W
    Acta Paediatr; 2005 Jul; 94(7):884-9. PubMed ID: 16188810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
    Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
    Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation.
    Koestenberger M; Cvirn G; Gallistl S; Baier K; Leschnik B; Muntean W
    J Thromb Thrombolysis; 2004 Aug; 18(1):5-10. PubMed ID: 15744547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A step change in oral anticoagulation: lack of coagulation monitoring with ximelagatran.
    Carlsson SC; Schulman S
    Semin Vasc Med; 2005 Aug; 5(3):259-65. PubMed ID: 16123913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of melagatran on activated partial thromboplastin time and on ecarin clotting time in cord versus adult plasma.
    Koestenberger M; Gallistl S; Bettina L; Cimenti C; Kutschera J; Cvirn G
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):677-80. PubMed ID: 17102656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies.
    Lee FM; Chan AK; Lau KK; Chan HH
    Thromb Res; 2014 May; 133(5):705-13. PubMed ID: 24666649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.
    Elg M; Börjesson I; Carlsson S
    Biopharm Drug Dispos; 2003 Sep; 24(6):251-7. PubMed ID: 12973822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor.
    Hayashi T; Tanaka I; Shima M; Yoshida K; Fukuda K; Sakurai Y; Matsumoto T; Giddings JC; Yoshioka A
    Haemophilia; 2004 Jul; 10(4):397-400. PubMed ID: 15230956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
    Johansson S; Wåhlander K; Larson G; Ohlsson L; Larsson M; Eriksson UG
    Blood Coagul Fibrinolysis; 2003 Oct; 14(7):677-84. PubMed ID: 14517494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
    Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
    Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.
    Gustafsson D; Antonsson T; Bylund R; Eriksson U; Gyzander E; Nilsson I; Elg M; Mattsson C; Deinum J; Pehrsson S; Karlsson O; Nilsson A; Sörensen H
    Thromb Haemost; 1998 Jan; 79(1):110-8. PubMed ID: 9459334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
    Shirasaki Y; Morishima Y; Shibano T
    Thromb Res; 2014 Apr; 133(4):622-8. PubMed ID: 23932349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
    Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
    Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat.
    Elg M; Gustafsson D; Carlsson S
    Thromb Res; 1999 May; 94(3):187-97. PubMed ID: 10326765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa.
    Kaku S; Suzuki M; Saitoh M; Funatsu T; Uemura T; Suzuki K; Iwatsuki Y; Kawasaki T
    Thromb Res; 2013 May; 131(5):450-6. PubMed ID: 23591155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.